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ABSTRACT
Hepatitis B virus [HBV] infection is a worldwide problem resulting in many deaths yearly from cirrhosis and liver
cancer. Regrettably also, healthcare workers get exposed to blood-borne pathogens, including hepatitis B virus at 
work. HBV infection in immuno-competent hosts results in acute fulminant illness which may be fatal, partially 
resolved to become chronic, or completely resolved. HBV immunization in the country cover neonates and health 
workers leaving many people uncovered. Lack of monitoring and confirmation of successful HBV immunization in 
heath workers reduces coverage in this group leaving many susceptible to HBV infection at work. We aimed to 
determine the magnitude of this risk for occupational exposure to HBV infection. We therefore analyzed sixty nine 
routine blood samples coming to our Haematology laboratory at Irrua, Edo, Nigeria, using the five parameter 
hepatitis B virus kit manufactured by Micropoint Diagnostics USA. Results showed that HBsAg, Ant-HBs, HBeAg, 
Anti-HBe and Anti-HBc were reactive in 11.6%, 23%, 1.4%, 7% and 7% of our study samples indicating that the 
burden of HBV infectivity is high. We recommend active monitoring and routine confirmation of successful HBV 
immunization in health workers with expansion of the program to cover more of our population. 
Key Words: Chronic HBV Infection, Occupational exposure, Immunization, Management of Chronic HBV 
infection 
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INTRODUCTION 
In the line of duty, Health Care Workers are at risk of 
contacting a number of infectious agents whose 
concentrations in human body fluids (especially in 
whole blood, serum or plasma) can be particularly 
high during the incubation and/or acute stages of 
these infections. These agents include the Hepatitis B 
Virus (HBV), Hepatitis C Virus (HCV) and types I 
and II Human Immunodeficiency Virus (HIV I &II) 
among others. 
HBV infection however, is a worldwide health 
problem. The World Health Organization (WHO) 
estimates that approximately more than two billion 
people have been infected with HBV. Of these, 
approximately 240 million are chronically infected 
and are at risk of serious illnesses and death from 
Cirrhosis and Hepato-Cellular Carcinoma (HCC) -
diseases that are estimated to cause approximately 
600,000 deaths every year worldwide (FitzSimons, et 
al. 2008; CDC 2008; WHO, 2004). Majority of the 
people infected with HBV live in Asia and Africa;
particularly Sub-Saharan Africa (Custer, et al., 2004). 
The routes of transmission of HBV infection include; 
Mother to child transmission, direct contact with an 
infected person during early childhood, Hetero- and 
Male Homo-sexual activity, injection drug use, 
muco-cutaneous contact with infected body fluids 
and body fluid contaminated surfaces (occupational 
exposure) and iatrogenic infections via blood and 
blood product transfusion and transplantation of solid 
organs (especially liver) to susceptible individuals 
(Goldstein, et al., 2005; Horvat, et al., 2011). 
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The HBV virus is a partially double stranded DNA 
virus of the hepadnaviridae (hepatotropic DNA virus) 
family (Ganem et al., 2004). Hepadnaviridae have a 
strong preference for infecting liver cells, though 
small amounts have been found in kidneys, pancreas 
and mononuclear cells. The virion (Dane particle) is 
composed a nucleocapsid core surrounded by a host 
derived lipid membrane containing the Hepatitis B 
surface Antigen (HBsAg). The nucleocapsid core 
contains the Hepatitis B core Antigen (HBcAg) 
surrounding the Hepatitis B e-Antigen (HBeAg), a 
single molecule of partially double stranded circular 
DNA, and a DNA dependent polymerase (Horvat et 
al., 2011; Ganem et al., 2004). The highly efficient 
genome of this virus contains four Open Reading 
frames/regions which code for the viral structural and 
attachment proteins (HBsAg, HBcAg and HBeAg) 
and proteins needed for replication (viral polymerase 
and X protein). Following attachment and entry into 
the hepatocyte, the virion is un-coated and migrates 
to the nucleus where it is converted into a covalently 
closed circular DNA (cccDNA) by the host 
polymerase. The cccDNA serves as the template for 
the transcription of the pre-genomic RNA (pgRNA) 
and mRNA (Ganem et al., 2004)
The transcribed pgRNA translocates into the 
cytoplasm where it serves as the template for the 
reverse transcription enzyme as well as the core 
protein. Simultaneously, the polymerase converts 
some pgRNA into cccDNA, some of which circulate 
back into the nucleus to build up and maintain the 
pool of cccDNA in early/acute infection. Four viral 
mRNA transcripts (transcribed from various 
promoter regions on the cccDNA) are translated into 
HBV proteins (Horvat et al., 2011; Ganem, et al., 
2004). The longest mRNA acts as the template for 
genomic replication (pgRNA) as well as the 
translation of the precore-core (HBcAg) and 
polymerase proteins. The HbeAg is cleaved from the 
HBcAg during viral assembly prior to viral release. 
The second and third transcripts are translated into 
proteins (preS1, preS2 and S proteins) that constitute 
the HBsAg which is usually produced in excess 
during active viral replication and circulates as non 
infective immunogenic empty viral particles. The 
fourth and smallest transcript encodes the X protein 
which transactivates transcription. The pgRNA and 
the polymerase protein are packaged into HBcAg 
within which the reverse transcriptase enzyme 
synthesizes a new viral DNA genome. These 
particles are then transported to the HBsAg in the ER 
of the host cell and HBeAg is cleaved off the HBcAg 
into the circulation (where it circulates freely, or 
bound to albumin, globulin or α1 antitrypsin) prior to 
viral release. Thus during active viral replication, 
antigens such as HBsAg, HBeAg, and Viral DNA are 
detectable in the patient’s circulations using 
molecular and serologic assays (Horvat et al., 2011;
Ganem et al., 2004). HBcAg is undetectable because 
the antigen does not circulate freely in blood (Horvat 
et al., 2011; CDC, 2008). Similarly, with vigorous 
host immune response, antibodies to HBsAg (Anti-
HBs), HBeAg (Anti-HBe) and HBcAg (Anti-HBc) 
are produced and become detectable by serological 
assays during various stages of the infection and 
convalescence as shown in table 1 below. 
Mutations within the viral genome could impact on 
prevention, detection and treatment of HBV infection 
by causing failure or defect of synthesis of HBeAg 
(preC gene mutation) or produce viruses that either 
cause false negative serological assay for HBsAg 
and/or unresponsiveness to vaccine-induced 
immunity and HBV immunoglobulin therapy 
(envelope gene) [Horvat et al., 2011; CDC, 2008; 
Ganem et al., 2004). 
The disease outcome of primary HBV infections 
depends on the age and immune status of the patient. 
Primary infections in immune-competent adults may 
be symptomatic (usually) or asymptomatic while that 
in neonates and young children and, immune-
compromised adults usually lead to chronicity. 
Symptomatic infections usually manifest, after an 
incubation period of 2-3 months (range: 6weeks to 6 
months), with non-specific symptoms and signs such 
as fever, abdominal pains, vomiting, jaundice and 
hepatomegaly. Acute infection is usually 
accompanied by high rate of viral replication (with 
high levels of circulating HBsAg, HBeAg and HBV 
DNA) and infectivity (Horvat, et al., 2011, CDC, 
2008; Ganem et al., 2004; Liang, 2009). It also 
provokes vigorous host immune response with 
production of Anti-HBs and Anti-HBc and liver 
damage majorly from the effects of  inflammatory 
bye products such as; Tumor Necrosis Factor (TNF), 
Free Radicals and proteases and, to a lesser extent, 
direct Lymphocyte cytotoxicity by CD8+ T- cells and  
Natural Killer cells. This immune response often lead 
to viral clearance attributable to the immune response 
cells as well as inflammatory bye products notably 
TNF-α and Interferon-γ (IFN-γ) which kill the viruses 
without damaging liver cells (Guidotti, et al., 1996;
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Baron, et al., 2002). This may be followed by 
complete recovery (Symptoms, Viral replication and 
liver damage stops, No HBV antigen in serum and 
seroconversion to Anti-HBs, Anti-HBe and Anti-
HBc), fulminant hepatitis with mortality (continued 
viral replication, host immune response and liver 
damage) or progress to a chronic infection. The first 
two antibodies may wane over time leaving Anti-
HBc as the only serologic evidence of the infection
(No symptoms but varying level of viral replication 
and host immune response) (Horvat et al., 2011;
Ganem et al., 2004). Majority of neonatal and early 
childhood infections as well as infections in the 
immune-compromised adults often lead to chronic 
carriage of the virus. Unfortunately, HBV infections 
resulting in chronic carriage of the virus are more 
common in the parts of the world where the disease is 
more prevalent because infections in these places 
occur mostly peri-natally and in early childhood (Lok 
et al., 2007; McMahon, 2005).  
Table 1: HBV markers in different stages of infection and convalescence [Modified from Horvat et al., 2011]




HBV specific antibody markers
HBsAg HBeAg Anti-HBc Anti-HBe Anti-HBs
Susceptible host - - - - - -
Early incubation + - - - - -
Late incubation + + -/+ - - -
Acute infection + + + + - -
Recent infectiona -/+ - - + + +++
Remote infectionb - or very low - - + +/- +
HBsAg negative acute 
infection
-(<103IU/ml) - - + - -
HBsAg variant 
infection
-/+ - -/+ + - -
Immune active carrier ++(>105IU/ml) + -/+ +++ - -
Inactive HBsAg carrier -(<103IU/ml) + - + + -
Immune tolerant carrier +++ + + + - -
Vaccination response - - - - - +
(a) Early convalescence and individuals who remain HBV DNA positive for a long time. (b) Individuals with 
anti-HBc in the absence of other serologic markers, including DNA. They may or may not have anti-HBs 
and may reactivate HBV during immunosupression.
Three phases of chronic HBV infection have been 
recognized; the immune tolerant phase characterized 
by HBeAg positive with high levels of HBV DNA 
and hence high infectivity but absence of active liver 
disease, the immune active or chronic hepatitis phase 
in which there is high level of HBV DNA and active 
liver inflammation with positive Anti-HBe and 
positive or negative HBeAg, and the inactive phase 
during which anti-HBe is detected but liver 
aminotransferase levels are normal with low or 
absent HBV DNA (Horvat, et al., 2011; CDC, 2008]. 
Patients can evolve through these phases or revert 
from inactive hepatitis to immune active infection at 
any time. The presence of HBeAg and HBV DNA 
generally indicate high viral replication and 
infectivity; the presence of anti-HBe usually indicates 
decreased or undetectable HBV DNA levels and 
lower levels of viral replication (Horvat, et al., 2011). 
However, HBV DNA have been found at infective 
doses in a small proportion of donors from the 
Brazilian Amazon designated as having occult HBV 
infection (Moresco et al., 2014).
Health workers are at a high risk of contacting HBV 
infection in the workplace via muco-cutaneous 
exposure to infectious blood and blood products 
(WHO, 2003). Spilled infectious body fluid 
containing HBV remain infectious on the 
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contaminated surfaces for about a week after spillage, 
if the surface is not appropriately disinfected when 
spillage occurred (Horvat et al., 2011; CDC, 2008). 
Vaccinations against HBV has been introduced for 
health workers and neonates for some times now in 
this country but the vast majority of patients whose 
body fluids are being processed daily in our 
laboratories are adults, who escaped the neonatal 
vaccination coverage, or non health workers, who are 
thus not covered by the health worker vaccination 
program. Anecdotal reports unfortunately show that 
some health workers somehow manage to either not 
get immunized at all or fail to complete their HBV 
vaccination. In addition post vaccination screening 
for and measurement of ant-HBs levels in Health 
workers to confirm success of vaccination is not 
routinely done in Nigeria as is recommended in other 
countries; both the WHO and CDC recognize levels 
of 10mIU/ml of anti-HBs as protective (CDC, 1991]. 
We undertake in this study to estimate the burden of 
and infectivity profile of routine blood samples for 
HBV in the Haematology laboratory of Irrua 
Specialist Teaching Hospital with a view to making 
recommendations on confirmation of successful 
vaccination and other necessary subsequent 
interventions.
MATERIALS AND METHODS
Sample Size: A total of sixty Nine (69) consecutive 
routine blood samples in the Haematology 
Laboratory of Irrua Specialist Teaching Hospital, 
Irrua, were selected for this study in May 2012 after 
the requested test had been performed. The samples 
were centrifuged and plasma separated into plane 
bottles and refrigerated at 4oC until analysis. 
Exclusion Criteria: The samples sent for HBV 
screening, HCV screening and, screening for HIV 
and syphilis were not selected for this study. Also 
excluded were samples of blood donors. 
Ethical Consideration: Ethical approval was sort 
and obtained from the Research and Ethical Review 
Committee of the Irrua Specialist Teaching Hospital.
Data Collection: Socio-demographic characters such 
as the age and sex of the patients as well as the types 
of tests requested by the clinicians were extracted 
from the request form which normally accompany 
each sample and are recorded in a sheet against the 
sample number. However, the presumptive diagnoses 
could not be recorded as many forms lack 
information akin to those documented in studies by 
Ikponmwen et al. (2013) and Nutt et al. (2008).
Sample Analysis: The separated plasmas were 
analyzed for the presence of HBsAg, HBeAg, Anti-
HBs, Anti-HBe and Anti-HBc using the five 
parameter hepatitis B virus kit manufactured by 
Micropoint Diagnostics USA. Instructions of the 
manufacturers as contained in the product inserts 
were strictly followed. Positive samples were tested 
in duplicates and confirmed using control antigen or 
antibodies supplied by the manufacturer with the kit. 
Results were entered into and analyzed on 
spreadsheets of SPSS version 16.0 alongside the 
socio-demographic data earlier obtained.
RESULTS
The mean age of patients whose samples were 
analyzed was 28.30 (SD 19.13) with a range from 
Five months to Seventy seven years. Forty Two 
percent (29) and Fifty Eight Percent (40) of these 
samples belong to male and female patients 
respectively as show in the pie chart below.
Eight (11.6%) of the samples were reactive for 
HBsAg, Sixteen (16; 23%) of them were reactive for 
Anti-HBs. Only one sample (1.4%) was reactive for 
HBeAg while reactivity for Anti-HBe and Anti-HBc 
were seven in each case (10.1%) as shown in table 2 
below. 
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Table 2: Sero-positivity to HBV maker
HBV Maker Number [%] Positive/Reactive Number [%] Negative/Non-Reactive
HBsAg 08 [11.6%] 61 [88.4%]
Anti-HBs 16 [23%] 53 [76.8%]
HBeAg 1 [1.4%] 68 [98.6%]
Anti-HBe 7 [10.1%] 62 [89.9%]
Anti-HBc 7 [10.1%] 62 [89.9%]
Keys: HBsAg= Hepatitis B surface Antigen, HBeAg = Hepatitis B envelope Antigen, Anti-HBs = Antibodies to 
HBsAg, Anti-HBe = Antibodies to HBeAg, Anti-HBc = Antibodies to Hepatitis B core Antigen
Table 3: Sex distribution of HBV markers.














HBsAg 2 (6.9) 6 (15) 8 (11.6) 0.260
HBeAg 0 (0) 1 (2.5) 1 (1.4) 0.580
Anti-HBs 2 (6.9) 14 (35) 16 (23) 0.006
Anti-HBe 2 (6.9) 5 (12.5) 7 (10.1) 0.368
Anti-HBc 2(6.9) 5 (12.5) 7(10.1) 0.368
Figure 1: Gender of Patients
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The sex distribution of HBV marker positivity is 
shown in Table 3 above. Table 3 also shows that even 
though differences existed in the number of male and 
female samples that tested positive for various 
antigens and antibodies, this only reached statistical 
significance in the case of Anti-HBs were there were 
significantly more female samples testing positive 
than males. (p= 0.006)
DISCUSSION
Eleven percent of samples in our study are positive 
for HBsAg. This is consistent with the population 
estimate of >8% for regions of the world, with high 
endemicity for HBV infection, to which Nigeria 
belong. Our figure is however higher than the overall 
sero-positivity rate of 4.98% (Ejele and Ojule, 2005)
and 4.3% (Akani et al., 2005) found in routine 
samples and pregnant women in Port Harcourt 
respectively. Any of this patient could be incubating 
an acute infection, having acute hepatitis or be a 
chronic carrier all of which are infectious as shown in 
table 1 above (Horvat et al., 2011; CDC, 2008;
Ganem, et al., 2004). 
Twenty-three percent were positive for anti-HBs 
indicating that they had a recent or remote infection 
which has just resolve and some of these could still 
be infectious depending on the circulating HBV DNA 
level. Positivity for anti-HBe in our study was 10.1%. 
These patients could be have a resolving acute 
infection or could be chronic carriers of HBV.
Anti-HBc was detected in 10.1% of our samples. 
Positivity for this HBV antibody alone could indicate 
a recent, remote or inactive chronic infection in 
which anti-HBs had waned, or could be indicative of 
acute infection by an HBsAg variant in which HBs is 
not detected (Bertoletti and Gehring, 2007; 
Heermann, 1999.). It is also important to note that 
infective doses of HBV DNA were found in a 
significant proportion of Brazilian donors. The 
implication is that these samples are still highly 
infectious. 
Health workers are exposed to blood and other body 
fluids in the course of their work and are 
consequently at risk of infection with blood borne 
viruses including HIV; HBV and HCV. The risk of 
infection for health workers depends on the 
prevalence of the disease in the patient population 
and the nature and frequency of exposures. The most 
common form of occupational exposure to blood and 
the most likely to result in infection is needle stick 
injury while health workers who work in areas such 
as operating, Delivery and Emergency rooms and the 
laboratory are at a higher risk of exposure. Cleaners, 
waste collectors and others whose duties involve 
handling of blood-contaminated materials are also at 
risk. Among 35 million health workers worldwide, 
about 3million experience percutaneous exposure to 
blood borne pathogens every year; two million of 
those to HBV, 0.9million to HCV and 170,000 to 
HIV. These injuries may result in 70,000 HBV, 
15,000HCV and 1,000 HIV infections. More than 
90% of these infections occur in developing countries 
(WHO, 2003; FitzSimon et al., 2008].  
CONCLUSIONS AND RECOMMENDATIONS
With the forgoing, it is obvious that the risk of 
occupational exposure to HBV in our center is 
enormous considering the positivity rates of the 
infectivity markers for this virus in our study. We 
therefore recommend that; the training and retraining 
of health workers in the use of personal protective 
wears and, handling and disposal of body fluid and 
body fluid contaminated materials should be 
intensified; the routine immunization of health 
workers against HBV should be continued and 
properly monitored to prevent cases of default and/or 
failure to complete the schedule and routine 
screening and measurement of anti-HBs levels be 
commenced to monitor and confirm the success and 
effectiveness of HBV immunization of health 
workers so that necessary interventions can be 
instituted in cases of unsuccessful immunization . We 
also recommend that routine immunization of adults 
who escaped the routine childhood immunization 
against HBV should be seriously considered so that 
the burden of HBV infection in health workers 
through occupational exposure can be reduced. 
Finally, we are of the opinion that it is time to start 
active public health management of HBsAg positive 
persons through contact management, patient 
education, dedicated medical management of chronic 
hepatitis B and development of Surveillance 
registries for persons with Chronic HBV infection.
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